Back to search

Peptide record

TPDB42616

P08 Anticancer standard
16 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB42616
P08
Anticancer
Cancer-related peptides
CancerPPD 2.0
standard
No
A 16-aa standard natural anticancer peptide sequence curated from CancerPPD 2.0, with an available 3D structural model.
Sequence
NSNLVGAAHEELQQSR
Physicochemical Analysis
C71H117N25O27
DCIKMFPTWY
ANEQLS
1752.86
5.30
2
2
5
-1
6.69
-0.956
79.38
Mammalian: 1.4 hour Yeast: 3 min E.coli: >10 hour
0
0.00
6
Residue Composition
number
2
A
1
R
2
N
0
D
0
C
2
E
2
Q
1
G
1
H
0
I
2
L
0
K
0
M
0
F
0
P
2
S
0
T
0
W
0
Y
1
V
Amino Acid Distribution
A: 2 R: 1 N: 2 D: 0 C: 0 E: 2 Q: 2 G: 1 H: 1 I: 0 L: 2 K: 0 M: 0 F: 0 P: 0 S: 2 T: 0 W: 0 Y: 0 V: 1
Chemical Descriptors
16
C71H117N25O27
1752.86
5.30
-1
6.69
-0.956
Free
L
Linear
Free
Anticancer
Lamin A/C (LMNA) fragment
Evidence Records 2 records
Evidence 1 Activity

Activity

Relative viability
Relative viability = 0.92 at 50 µg/ml
Anticancer

Target

Bone Cancer
MG-63
Bone

Assay & Model

MTT assay
48-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2023

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

Relative viability
Relative viability = 1.06 at 50 µg/ml
Anticancer

Target

Bone Cancer
U-2 OS
Bone

Assay & Model

MTT assay
48-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2023